Lantheus Holdings, Inc. LNTH R2K
Company Overview
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Why Investors Should Care
Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 16.7%.
Revenue has grown at a 15.2% CAGR over the past five years.
Trades at a P/E of 24.4, below the sector median of 25.4.
Maintains a net profit margin of 18.0%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.54B (+0.5% YoY); net profit $233.56M.
- Trailing 12 Months Year-on-year growth — revenue +1.2%, earnings +76.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 15.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 15.15% |
| 1 Year: | 1.20% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 76.50% |
Stock Price Performance
| 1 Year: | +23.25% |
| 6 Months: | +51.52% |
| 3 Months: | +25.35% |
| 1 Month: | -1.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.24 · Neutral
P/E of 24.43 is below the sector median of 25.41 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 23.5%.
- Compounding revenue at 15.2% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LNTH Lantheus Holdings, Inc. R2K | 102.37 | 24.43 | $6.66B | 0.00% | 16.66% | 23.48% | 15.15% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 81.36M | 88.84M | 79.94M | 81.24M | 82.63M | 85.57M | 88.90M | 86.27M | 86.51M | 85.70M | 85.78M | 89.35M | 90.70M | 66.01M | 88.54M | 92.51M | 101.06M | 102.07M | 208.88M | 223.72M | 239.29M | 300.78M | 321.70M | 319.95M | 369.98M | 394.09M | 378.73M | 372.76M | 378.05M | 384.01M | 377.33M |
| Gross Profit | 32.76M | 35.77M | 32.67M | 33.70M | 33.38M | 33.70M | 35.75M | 33.68M | 34.65M | 39.76M | 45.95M | 38.53M | 37.90M | 42.31M | 43.85M | 44.88M | 43.84M | 44.08M | 44.57M | 41.59M | 44.56M | 38.00M | 25.85M | 36.26M | 41.03M | 46.09M | 42.67M | 129.07M | 138.03M | 147.43M | 77.08M | 202.65M | 199.95M | 241.85M | 255.77M | 242.13M | 237.70M | 241.01M | 222.37M | 230.92M |
| Operating Income | - | 11.38M | 5.36M | 13.41M | - | 17.67M | 14.18M | 12.60M | - | 11.93M | 17.90M | 12.82M | - | 15.14M | 15.93M | 16.48M | - | 16.17M | 14.54M | 8.52M | - | 7.12M | -5.54M | -5.25M | 15.62M | -26.78M | -14.33M | 58.92M | 63.20M | 85.74M | -9.34M | 124.14M | 112.36M | 106.64M | 102.73M | 133.74M | 102.07M | 87.97M | 43.62M | 81.33M |
| Net Income | 227.00K | 375.00K | -24.42M | 5.39M | 3.92M | 10.32M | 7.35M | 4.22M | 4.87M | 4.14M | 13.60M | 8.53M | 97.13M | 8.21M | 9.74M | 9.27M | 13.29M | 9.95M | 6.41M | 4.86M | 10.45M | 3.34M | -7.01M | -6.39M | 9.01M | -26.66M | -13.41M | 42.96M | 43.06M | 61.23M | -2.81M | 94.13M | 131.96M | 131.07M | 62.07M | 131.09M | 72.94M | 78.75M | 27.77M | 118.42M |
| Diluted EPS | - | 0.02 | -1.29 | 0.18 | 0.13 | 0.34 | 0.24 | 0.13 | 0.13 | 0.11 | 0.35 | 0.22 | 2.47 | 0.21 | 0.25 | 0.24 | 0.34 | 0.25 | 0.16 | 0.12 | 0.26 | 0.08 | -0.16 | -0.10 | 0.13 | -0.39 | -0.20 | 0.61 | 0.61 | 0.86 | -0.04 | 1.33 | 1.88 | 1.87 | 0.88 | 1.79 | 1.02 | 1.12 | 0.41 | 1.80 |
| R&D Expense | - | 6.20M | 2.64M | 2.46M | - | 3.04M | 2.61M | 2.85M | - | 5.35M | 5.24M | 3.55M | - | 3.99M | 4.21M | 4.32M | - | 4.93M | 5.79M | 4.86M | - | 4.05M | 4.42M | 11.68M | 10.36M | 12.06M | 11.25M | 12.20M | 14.73M | 12.52M | 30.53M | 15.90M | 14.45M | 48.02M | 60.60M | 24.15M | 36.31M | 45.49M | 48.02M | 39.38M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 283.67M | 301.60M | 293.46M | 301.85M | 331.38M | 343.37M | 347.34M | 339.41M | 425.21M | 935.06M | 1.30B | 1.53B | 1.54B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 353.36M | 586.89M | 545.62M | 599.66M |
| Gross Profit | 77.36M | 125.52M | 135.52M | 137.78M | 162.13M | 174.88M | 174.81M | 138.76M | 187.69M | 581.70M | 709.54M | 988.29M | 941.95M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 545.51M | 344.90M | 539.73M | 626.39M |
| Operating Income | -18.89M | 39.42M | 42.53M | 56.59M | 51.85M | 64.49M | 51.66M | -4.20M | -60.83M | 36.20M | 364.64M | 448.56M | 315.56M |
| EBITDA | - | - | - | - | - | - | - | - | - | 81.83M | 491.00M | 515.27M | 403.64M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 7.18M | 20.02M | 19.67M | 19.75M |
| Pretax Income | - | - | - | - | - | - | - | - | - | 26.72M | 410.94M | 430.98M | 313.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -1.35M | 84.28M | 118.53M | 80.23M |
| Net Income | -61.55M | -3.56M | -14.75M | 26.76M | 123.39M | 40.52M | 31.67M | -13.47M | -71.28M | 28.07M | 326.66M | 312.44M | 233.56M |
| Diluted EPS | - | -0.20 | -0.60 | 0.82 | 3.17 | 1.03 | 0.79 | -0.25 | -1.06 | 0.40 | 4.65 | 4.36 | 3.41 |
| R&D Expense | 30.46M | 13.67M | 14.36M | 12.20M | 18.12M | 17.07M | 20.02M | 32.79M | 44.97M | 311.68M | 77.71M | 168.10M | 177.31M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 243.15M | 242.38M | 255.90M | 383.86M | 439.83M | 405.92M | 869.82M | 863.78M | 1.32B | 1.65B | 1.98B | 2.23B |
| Total Equity | -173.10M | -235.52M | -239.27M | -185.29M | -106.52M | 23.29M | 71.00M | 114.60M | 514.21M | 464.44M | 447.15M | 815.89M | 1.09B | 1.09B |
| Cash & Equivalents | 33.32M | 18.58M | 19.74M | 28.60M | 51.18M | 76.29M | 113.40M | 92.92M | 79.61M | 98.51M | 415.65M | 713.66M | 912.81M | 359.12M |
| Long Term Debt | - | - | 392.86M | 349.86M | 274.46M | 265.39M | 263.71M | 183.93M | 197.70M | 163.12M | 557.71M | - | - | - |
| Total Liabilities | - | - | 482.42M | 427.67M | 362.41M | 360.57M | 368.83M | 291.32M | 355.62M | 399.35M | 874.11M | 835.26M | 892.33M | 1.14B |
| Current Liabilities | - | - | 48.53M | 35.52M | 43.84M | 46.75M | 52.76M | 66.11M | 80.50M | 90.50M | 247.70M | 187.35M | 240.53M | 333.42M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 21.76M | 49.64M | 54.78M | 61.19M | 80.38M | 16.40M | 53.92M | 281.78M | 305.26M | 544.75M | 390.14M |
| Investing Cash Flow | - | -13.15M | 3.28M | -16.31M | -19.13M | -22.06M | -4.91M | 3.68M | -276.55M | 5.94M | -226.01M | -627.17M |
| Financing Cash Flow | - | 999.00K | -30.22M | -13.45M | -4.67M | -78.88M | -21.86M | -39.33M | 311.69M | -13.06M | -118.54M | -316.58M |
| Share Buybacks | 106.00K | - | - | - | - | - | 0 | 0 | 75.00M | 0 | 100.00M | 300.02M |
| Dividends Paid | 123.00K | - | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 27.3% | 41.6% | 46.2% | 45.6% | 48.9% | 50.9% | 50.3% | 40.9% | 44.1% | 62.2% | 54.7% | 64.4% | 61.1% |
| Operating Margin % | -6.7% | 13.1% | 14.5% | 18.7% | 15.6% | 18.8% | 14.9% | -1.2% | -14.3% | 3.9% | 28.1% | 29.2% | 20.5% |
| Net Margin % | -21.7% | -1.2% | -5.0% | 8.9% | 37.2% | 11.8% | 9.1% | -4.0% | -16.8% | 3.0% | 25.2% | 20.4% | 15.2% |
| ROE % | 26.1% | 1.5% | 8.0% | -25.1% | 529.8% | 57.1% | 27.6% | -2.6% | -15.3% | 6.3% | 40.0% | 28.7% | 21.4% |
| ROCE % | - | 20.3% | 20.6% | 26.7% | 15.4% | 16.7% | 15.2% | -0.5% | -7.9% | 3.4% | 24.9% | 25.8% | 16.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.57% | 8.18M | $881.17M |
| 2 | Farallon Capital Management LLC | 8.58% | 5.58M | $601.23M |
| 3 | Janus Henderson Group PLC | 7.33% | 4.77M | $514.15M |
| 4 | FMR, LLC | 7.11% | 4.63M | $498.18M |
| 5 | Vanguard Portfolio Management LLC | 4.88% | 3.17M | $341.81M |
| 6 | Vanguard Capital Management LLC | 4.48% | 2.91M | $313.81M |
| 7 | State Street Corporation | 3.73% | 2.43M | $261.64M |
| 8 | American Century Companies Inc | 2.74% | 1.78M | $191.79M |
| 9 | Geode Capital Management, LLC | 2.71% | 1.77M | $190.16M |
| 10 | Morgan Stanley | 2.53% | 1.65M | $177.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LNTH
3 Reasons to Avoid LNTH and 1 Stock to Buy Instead - StockStory
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPQ3UwNEdtZzZ0bzRCQW9pUnB4clFGd3k2MVc5ZTM2TjZTSTBkcTFIc0tFVjIwOTd1c09RT1ZzWW01S0IzaGhieUQ4Q0RrNmdxYkxubnBLZjlzVmkxUmlSRm5lYjNKUkF0d2hVSlNzT2Q3cFk5VHl2Vjc4dkpGLThORjZ4Zkpib1M3alk1QW…
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A 4.44% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxQcVB2THhLQ0hmeDdsTmJYM1ZpR3I0YjF4UEJVMkhDWHkxZlVzVllBX2JtZlpGdEJNQ09kZEF0c3d1TWdyOXZadGN5VTl1R2RsWFpWQW44cVhkdGd4amtSRWJhQWwxMVMwT1g2NEhHYnZJQ2dQWG1sSlJSbDVxdjlKNENUV3ZOZW01N0QwQk…
Assessing Lantheus Holdings (LNTH) Valuation After Strong Multi Month Share Price Gains - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYkNrMm5kVFA5T2w0MkRzWlNTeW1SZzBleDE5RzJUQ0ZET2xmbERLVHk2MUk0OV9qMFpIeHJMb29zNGQzOEx5M0thUHFEaUx5V2pveGZKU2dCdXZiUHdlVFczT2xzVHk2dG9LVkdHTGpZaUVLRHVGbzhlQV9ZRFEtaVlyYkRfUE1JYThwcz…
Why Is LNTH Stock Up After Hours? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxON1dYZFMtUXZpcGx3YktJVnBld0JjX2diMFBsdktvUC1lZWZROWFxX1Mxd3Y5aFllUDlPNWs0WjRPbHRwbWhobTAxQlZxbWpWczdiU19LX2ZjUWlXWldYR21LMGFWX0ZBbDA0U3B3U2ZCRFA3RWxyOWt6NDh0TmMtY250LVlYeF9SUExNWn…
Lantheus (LNTH) Q4 2024 earnings summary - Quartr
<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE1MWlUzWEhSLWhKZVNvc2RmcVR2NEJDS0laMGh6WmNVNFVHWTF0djJuODd1OTlvem9vellVVW5pNFBEQV9Bd255dWc3ZGtmaUFrUlkwcTRjV3hwODBoclRRZno5MXNzalU?oc=5" target="_blank">Lantheus (LNTH) Q4 2024 earn…
Lantheus Holdings Inc (LNTH) Stock Down 6.4% but Still Overvalued -- GF Score: 82/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOdVVGZEt4UDFkMGZGaTdMYlhiQ2M4eE9Ca3JfYk1HU256MWM4NXZMM0JaWGtkR2t4anNCT24zcS1mUlJwZ21udW5jajZSN05icVRxVmxhMnltOWYtRWc3SC0tTTZQRkZDakY1ajJpZnl0OWF6YVF4NjVET1BCUG9FNHlZcjlqbUsyQXNnUG…
LNTH — Frequently Asked Questions
What is the current share price of Lantheus Holdings, Inc. (LNTH)?
As of 2026-07-14 21:23 PDT, Lantheus Holdings, Inc. (LNTH) trades at $102.37 on NasdaqGM. Its 52-week range is $50.11 to $110.94.
What is the market capitalisation of LNTH?
Lantheus Holdings, Inc. (LNTH) has a market capitalisation of $6.66B on NasdaqGM.
What is the P/E ratio of LNTH?
LNTH trades at a trailing price-to-earnings (P/E) ratio of 24.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.61.
What is the return on equity (ROE) of LNTH?
LNTH has a return on equity (ROE) of 23.48%. Its return on capital employed (ROCE) is 16.66%.
Is LNTH a good stock to buy?
This page provides a data-driven analysis of Lantheus Holdings, Inc. (LNTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.